PLGA 50:50 – PEG | DLG505P4

DLG505P4 is a Tri-block co-polymer of Poly DL-lactide co Glycolide with an average molecular weight ~50,000 and Polyethylene glycol molecualr weight ~4000.

It is supplied in the form of white coloured powder.

DLG505P4 is primarily used for sustained release drug delivery applications and for medical devices

CAS No:
952111-10-3

Manufacturing Process:
Ring-Opening

Molecular Formula:
[C3H4O2]m. X [C2H2O2]n X [C2H4O]x

Synonyms:
PLGA-PEG-PLGA,
Poly(ethylene glycol)-block-poly(lactic-co-glycolic) acid,
Poly(ethylene glycol)-block-poly(lactide-co-glycolide),
Lactic acid – Glycolic acid polyester-block-poly(ethylene oxide)

SKU: DLG505P4 Categories: ,
Get Quote

Additional information

Appearance

Molecular Weight

PLGA (Mw) : ~50,000 da, PEG (Mw) : ~4000 da

Ratio

lactide:glycolide (50:50)

Enhanced Drug Release of PLGA Nanoparticle Modified with Polymers: Chitosan

Abstract: The biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) is a biomaterial with great potential as a drug delivery carrier and a... Read More

Size Optimization Bromelain Loaded Nanocarriers by Box Behnken Design

ABSTRACT Bromelain (BRN) is an extensive product of investigation, regarded as effective naturally produced anticancer agents. Heterogeneity of tumors amongst... Read More

CENTRAL COMPOSITE FACE-CENTERED DESIGN-BASED FAVIPIRAVIR-LOADED PLGA

ABSTRACT Objective: The objective of this study is to fabricate favipiravir-loaded PLGA nanoparticulate systems that can increase the solubility along... Read More

Inhalable dry powder containing lipid polymer hybrid nanoparticles of Nintedanib esylate: In vitro and in vivo evaluations

Abstract: The key objective of this research work was to develop and evaluate dry powder for inhalation containing lipid polymer... Read More

SURFACE MODIFIED POLYMERIC NANOPARTICLES FOR ENHANCING DRUG DELIVERY OF METHOTREXATE IN THE BRAIN BY BLOCKING EFFLUX TRANSPORTERS

Abstract: The aim of the present study was to develop, optimize, and evaluate methotrexate containing poloxamer 407 coated polymeric nanoparticles... Read More

Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds

Abstract Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The standard... Read More

Formulation and Evaluation of Pralidoxime-PLGA Microspheres as Antidote against Organophosphorus Poisioning

Abstract Objective: The objective of the present work is to formulate and evaluate Pralidoxime chloride (PAM)-controlled release microspheres using poly... Read More

A tailored solution for localized drug delivery in liver cancer treatment

ABSTRACT Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently.... Read More

**Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma

Polymeric lipid hybrid nanoparticles (PHLNPs) are core-shell nanoparticle structures made up of polymer cores and lipid shells that have properties similar to both polymeric nanoparticles and liposomes. Methotrexate (MTX) loaded PLHNPs containing tween 80, phosphatidylcholine, poly D,... Read More

**Statistically designed vitamin D3 Encapsulated PLGA **microspheres dispersed in thermoresponsive in-situ gel for nasal delivery

Vitamin D deficiency is a cause of concern across the world. It is a fat-soluble vitamin and exhibits two molecular forms (D2 and D3). The aim of the present study is the development and optimization of vitamin D3 loaded PLGA microspheres by using Box Behnken Design. Additionally, to enhance nasal... Read More

Load More

Get Quote for PLGA 50:50 - PEG | DLG505P4